Saint Luke's Research

Saint Luke's Research

Advancing patient care and population health through innovative research

Research has been the heart of Saint Luke’s for more than 135 years. Saint Luke’s Research strives to continuously improve the quality and value of health care as a national leader in clinical, translational, and outcomes research. Our mission is to advance the prevention and treatment of disease, helping patients live healthier and longer lives.

Saint Luke’s Office of Research Services works with Saint Luke’s affiliated researchers across the health system to make research more effective by assisting with planning, implementation, and logistics. Research Services offers the support infrastructure to further strengthen Saint Luke’s role as a national leader in research.

 

OFFICE OF RESEARCH SERVICES

Provides a centralized and comprehensive infrastructure for research at Saint Luke’s.

Learn more

RESEARCH PROGRAMS

Saint Luke’s physicians within our institutes participate in industry-leading research.

CLINICAL TRIALS

Research studies at Saint Luke’s need participants of all ages and backgrounds.

Browse current studies

Support advanced research

Donor generosity enables our health system to investigate, identify, and provide the safest, innovative technologies and state-of-the-art treatments possible to patients now and for generations to come. Create a healthier tomorrow by investing in clinical research today.

News

Oct. 27, 2023
TCDMD: TRILUMINATE Deep Dive Clarifies 'Meaningful' Quality of Life Gains with Tricuspid TEER
Dr. Suzanne Arnold presented findings from the pivotal TRILUMINATE trial.
Oct. 25, 2023
New York Times: Even Short Runs Have Major Health Benefits
Dr. James O'Keefe explains why even short runs have major health benefits.
Oct. 13, 2023
Cardiovascular Business: Flurpiridaz Will Have a Major Impact on Cardiac PET and Nuclear Imaging
Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.
Sep. 21, 2023
Healio: Minimally Symptomatic Patients Likely to Survive with Good Health Status After TAVR
Dr. Chetan Huded and colleagues found patients with minimal symptoms who underwent TAVR were more likely to survive with good health status at one year than more symptomatic patients.
Sep. 12, 2023
TCTMD: Nonwhite Cardiac Arrest Victims Are More Likely to Die Prehospital: Why?
TCTMD talked to Dr. Paul Chan and Dr. Anezi Uzendu about the new study's findings.
Sep. 7, 2023
KSHB: Kansas City Doctors Are at Center of Breakthrough Research for Heart Failure Patients
KSHB talked to Dr. Mikhail Kosiborod, a cardiologist at Saint Luke’s Mid America Heart Institute and the study’s lead investigator, and Nancy Collins, a patient who was enrolled in the study.
Aug. 28, 2023
New York Times: Obesity Treatment Relieves Heart Failure Symptoms, Drugmaker’s Study Finds
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.
Aug. 26, 2023
CBS Evening News: Study Shows Wegovy May Reduce Risk of Heart Failure
The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Aug. 26, 2023
Good Morning America: New Study Highlights Benefits to Weight Loss Drugs
Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.
Aug. 25, 2023
U.S. News & World Report: Wegovy May Be Valuable New Option for Heart Failure Patients
Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.
Aug. 25, 2023
CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Jul. 28, 2023
U.S. News & World Report: Asian-Americans Less Likely to Survive Cardiac Arrest Despite Equal CPR Efforts
Asian adults in the U.S. who suffer cardiac arrest are less likely to survive than white adults, despite similar rates of receiving bystander CPR.